Physician profile
Timothy Wong
NPI 1275731739
$9,817.36
in general payments reported to CMS, 2019-2025
24 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,477 · 2020: $341 · 2021: $892 · 2022: $634 · 2023: $1,158 · 2024: $1,217 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,472.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,588.95 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,275.73 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,352.20 | 2019-2025 | Linzess, Viberzi, Creon |
| Merck Sharp & Dohme LLC | $429.93 | 2019-2024 | Dificid |
| Pfizer INC. | $253.41 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $253.36 | 2023-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $235.38 | 2021-2023 | |
| Redhill Biopharma INC. | $223.43 | 2020-2023 | Aemcolo, Movantik, Talicia |
| Intercept Pharmaceuticals, INC. | $221.11 | 2019-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $174.05 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $163.08 | 2025 | Rezdiffra |
| Allergan, INC. | $114.97 | 2019-2020 | |
| Medtronic, INC. | $110.96 | 2025 | Interstim |
| Vivus LLC | $88.34 | 2024-2025 | Pancreaze |
| Cumberland Pharmaceuticals, INC. | $60.16 | 2023 | Kristalose |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $53.58 | 2023-2024 | Capsocam Plus |
| Ardelyx, INC. | $48.11 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $42.74 | 2023 | Sutab |
| Janssen Biotech, INC. | $29.30 | 2022 | |
| Exact Sciences Corporation | $24.96 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $23.46 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $23.31 | 2025 | Dupixent |
| W. L. Gore & Associates, INC. | $14.98 | 2021 | |
| Globus Medical, INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.